PVA
Click for more information
0.00% $2.99 psivida corp.

latest analyst news fda approval in doubt

  1. beep
    38 Posts.
    clock Created with Sketch.
    28/10/10
    11:35
    Post #: 7397690
    latest analyst news is that complication rate of cataracts 87% and increases in intraocular pressure which if uncontrolled could lead to blindness are casting doubt about FDA approval. I guess thats the risk in biotech investing
    PVA Price at posting: $5.88 Sentiment: Sell Disclosure: Held
    Likes Created with Sketch.  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

ABY Adore Beauty FY24 revenues up 7.4% YoY to $196M
right-arrow Created with Sketch.
EVN Evolution shares up 3% on quarterly results for June showing rise in gold production
right-arrow Created with Sketch.
IMR Imricor raises $35M to pursue growth and expansion into Australia and NZ
right-arrow Created with Sketch.
NEWS Talking Australia's very competitive property landscape: Realty Talks
right-arrow Created with Sketch.
FMG Andrew Forrest was seemingly possessed by the spirit of hydrogen – now he's cut 700 jobs and canned FFI
right-arrow Created with Sketch.
AUN Aurumin reports high-grade iron ore rock chips at Central Sandstone, WA
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PVA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.